Gyre Therapeutics' stock is volatile - I'm upholding ... but their outstanding efficacy and good safety profiles has seen them secure label expansions into indications such as cardiovascular ...

Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) is expected to be releasing its earnings data before the market opens on Tuesday, March 25th.Analysts expect Gyre Therapeutics to post earnings ...

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Gyre Therapeutics (GYRE – Research Report), with a price target of $20.00. The company’s shares ...

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report)’s stock price gapped down prior to trading on Tuesday following a weaker than expected earnings announcement. The stock had previously ...

Earnings per share (EPS) missed analyst estimates by 71%. In the last 12 months, the only revenue segment was Gyre Pharmaceuticals contributing US$105.8m. The largest operating expense was Sales ...

The stock price didn't jump after Gyre Therapeutics, Inc. (NASDAQ:GYRE) posted decent earnings last week. We did some digging and believe investors may be worried about some underlying factors in ...

SAN DIEGO - Gyre Therapeutics (NASDAQ:GYRE) reported fourth quarter revenue of $27.87 million and provided full year 2025 revenue guidance that fell short of analyst expectations. The commercial-stage ...

Urimai deputy chairman David Marshel has called on the government to work with Google to remove the “illegal temple” label which appears alongside Hindu temples searched on Google Maps.

(NEXSTAR) — Some may have the chance to see the northern lights on Sunday thanks to an eruption of solar material colliding ...